Preferred Label : pyridazines;
MeSH definition : Six-membered rings with two adjacent nitrogen atoms also called 1,2-diazine.;
MeSH annotation : do not confuse with PYRAZINES;
Is substance : O;
Origin ID : D011724;
UMLS CUI : C0034250;
Allowable qualifiers
Automatic exact mappings (from CISMeF team)
Ne pas confondre avec
Record concept(s)
Related MeSH Supplementary Concept(s)
- A 80b [MeSH Supplementary Concept]
- ACY1083 [MeSH Supplementary Concept]
- AMG 208 [MeSH Supplementary Concept]
- ASP5642 [MeSH Supplementary Concept]
- AZD3514 [MeSH Supplementary Concept]
- AZD5153 [MeSH Supplementary Concept]
- CK 103A [MeSH Supplementary Concept]
- CK 112 [MeSH Supplementary Concept]
- CK 116 [MeSH Supplementary Concept]
- CK 119 [MeSH Supplementary Concept]
- CL 9673 [MeSH Supplementary Concept]
- CM-118 [MeSH Supplementary Concept]
- EVT-101 [MeSH Supplementary Concept]
- F 2692 [MeSH Supplementary Concept]
- FK3453 [MeSH Supplementary Concept]
- GSK4027 [MeSH Supplementary Concept]
- HCL 31D [MeSH Supplementary Concept]
- HPS 10 [MeSH Supplementary Concept]
- IMB5043 [MeSH Supplementary Concept]
- K00135 [MeSH Supplementary Concept]
- K00486 [MeSH Supplementary Concept]
- L82-G17 [MeSH Supplementary Concept]
- MCI 154 [MeSH Supplementary Concept]
- MF 438 [MeSH Supplementary Concept]
- MFT 279 [MeSH Supplementary Concept]
- ML-265 [MeSH Supplementary Concept]
- MOL 294 [MeSH Supplementary Concept]
- NIP 502 [MeSH Supplementary Concept]
- NPD-001 [MeSH Supplementary Concept]
- NSP 804 [MeSH Supplementary Concept]
- NSP 805 [MeSH Supplementary Concept]
- NVS-SM2 [MeSH Supplementary Concept]
- NZ 107 [MeSH Supplementary Concept]
- PCS1055 [MeSH Supplementary Concept]
- R 61837 [MeSH Supplementary Concept]
- R 66703 [MeSH Supplementary Concept]
- R 78206 [MeSH Supplementary Concept]
- RS 1893 [MeSH Supplementary Concept]
- SAR707 [MeSH Supplementary Concept]
- SCA 44 [MeSH Supplementary Concept]
- SP230 [MeSH Supplementary Concept]
- TAK 225 [MeSH Supplementary Concept]
- TT-301 [MeSH Supplementary Concept]
- U 97018 [MeSH Supplementary Concept]
- VX-745 [MeSH Supplementary Concept]
- Y 23684 [MeSH Supplementary Concept]
- ZD 9379 [MeSH Supplementary Concept]
- minozac [MeSH Supplementary Concept]
- pyrazon [MeSH Supplementary Concept]
Semantic type(s)
Six-membered rings with two adjacent nitrogen atoms also called 1,2-diazine.
https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/medeffet-canada/infovigilance-produits-sante/juin-2021.html#a5.4
2021
false
false
false
Canada
French
English
drug approval
canada
drug information
tepotinib
administration, oral
adult
carcinoma, non-small-cell lung
c-Met Inhibitor
protein kinase inhibitors
tepotinib
neoplasm metastasis
piperidines
pyridazines
pyrimidines
---
https://www.has-sante.fr/jcms/p_3191481/fr/ambrisentan-ohre-pharma
2020
false
false
false
France
drugs, generic
ambrisentan
evaluation of the transparency committee
ambrisentan
phenylpropionates
pyridazines
phenylpropionates
pyridazines
---
https://www.has-sante.fr/jcms/p_3184674/fr/ambrisentan-mylan
2020
false
false
false
France
drugs, generic
ambrisentan
evaluation of the transparency committee
ambrisentan
phenylpropionates
pyridazines
phenylpropionates
pyridazines
---
https://www.has-sante.fr/jcms/p_3185845/fr/ambrisentan-teva
2020
false
false
false
France
drugs, generic
ambrisentan
evaluation of the transparency committee
ambrisentan
phenylpropionates
pyridazines
---
https://www.has-sante.fr/jcms/p_3169251/fr/ambrisentan-reddy-pharma
2020
false
false
false
France
drugs, generic
ambrisentan
evaluation of the transparency committee
ambrisentan
phenylpropionates
pyridazines
---
https://www.has-sante.fr/jcms/p_3217751/fr/intelence
2020
false
false
false
France
etravirine
etravirine
insurance, health, reimbursement
treatment outcome
anti-hiv agents
administration, oral
reverse transcriptase inhibitors
child
drug therapy, combination
HIV-1
hiv infections
guidelines for drug use
evaluation of the transparency committee
pyridazines
---
https://www.has-sante.fr/portail/jcms/c_2972771/fr/intelence
2019
false
false
false
France
insurance, health, reimbursement
etravirine
evaluation of the transparency committee
pyridazines
---
https://www.ema.europa.eu/en/medicines/human/EPAR/ambrisentan-mylan
2019
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
drugs, generic
ambrisentan
ambrisentan
antihypertensive agents
antihypertensive agents
ambrisentan
hypertension, pulmonary
adult
drug therapy, combination
administration, oral
Endothelin A Receptor Antagonists
Endothelin A Receptor Antagonists
aged
drug interactions
pregnancy
breast feeding
fertility
drug evaluation, preclinical
phenylpropionates
pyridazines
phenylpropionates
pyridazines
---
https://www.has-sante.fr/jcms/p_3135595/fr/ambrisentan-accord
2019
false
false
false
France
French
drugs, generic
evaluation of the transparency committee
ambrisentan
ambrisentan
Perianal abscess
generations
dandruff
devices
tablets
family characteristics
Brain abscess
device, nos
Set, Psychology
seborrhea sicca
dandruff
equipment and supplies
phenylpropionates
pyridazines
phenylpropionates
pyridazines
---
https://www.has-sante.fr/portail/jcms/c_2780980/fr/iclusig
2017
false
false
false
France
French
evaluation of the transparency committee
administration, oral
ponatinib hydrochloride
ponatinib
ponatinib
imidazoles
pyridazines
---
http://www.has-sante.fr/portail/jcms/c_2751870/fr/volibris
https://www.has-sante.fr/portail/jcms/c_2751870/fr/volibris-ambrisentan-antihypertenseur
2017
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
drug therapy, combination
treatment outcome
hypertension, pulmonary
ambrisentan
ambrisentan
adult
Tadalafil
administration, oral
orphan drug production
ambrisentan
phenylpropionates
pyridazines
phenylpropionates
pyridazines
phenylpropionates
pyridazines
---
http://www.has-sante.fr/portail/jcms/c_2623462/fr/iclusig
2016
false
true
false
France
French
evaluation of the transparency committee
ponatinib hydrochloride
ponatinib
administration, oral
treatment outcome
antineoplastic agents
leukemia, myeloid, accelerated phase
blast crisis
leukemia, myeloid, chronic-phase
leukemia, lymphocytic, acute, L2
protein kinase inhibitors
orphan drug production
insurance, health, reimbursement
protein-tyrosine kinases
Tyrosine Kinase Inhibitors
precursor cell lymphoblastic Leukemia-Lymphoma
ponatinib
imidazoles
pyridazines
---
http://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Medicaments-ciblant-BCR-ABL-Imatinib-Dasatinib-Nilotinib-Bosutinib-Ponatinib-Medicament-ciblant-JAK-Ruxolitinib-Anticancereux-par-voie-orale-informer-prevenir-et-gerer-leurs-effets-indesirables
2016
false
false
false
France
French
practice guideline
antineoplastic agents
administration, oral
Drug-Related side effects and adverse reactions
Drug-Related side effects and adverse reactions
information dissemination
patient education as topic
drug interactions
Dasatinib
Imatinib Mesylate
fusion proteins, bcr-abl
protein kinase inhibitors
dasatinib
imatinib
nilotinib
nilotinib
bosutinib
ponatinib
ruxolitinib
janus kinases
ponatinib
ruxolitinib
bosutinib
continuity of patient care
pregnancy
Tyrosine Kinase Inhibitors
nilotinib
ruxolitinib
aniline compounds
nitriles
quinolines
imidazoles
pyridazines
pyrimidines
pyrazoles
---
http://www.has-sante.fr/portail/jcms/c_2629887/fr/zimino
2016
false
false
false
France
French
evaluation of the transparency committee
infusions, intravenous
treatment outcome
Levosimendan
Levosimendan
levosimendan
Product containing precisely levosimendan 2.5 milligram/1 milliliter conventional
release solution for injection (clinical drug)
heart decompensation
acute disease
adult
cardiotonic agents
cardiotonic agents
emergency treatment
risk management
heart failure
hydrazones
pyridazines
hydrazones
pyridazines
Simendan
Simendan
---
BCR-ABL Tyrosine Kinase Inhibitors [GLEEVEC (imatinib mesylate), TASIGNA (nilotinib),
BOSULIF (bosutinib), SPRYCEL (dasatinib), ICLUSIG (ponatinib hydrochloride)] - Risk
of Hepatitis B Reactivation
https://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2016/58222a-fra.php
2016
false
false
false
Canada
French
English
pharmacovigilance note
fusion proteins, bcr-abl
protein kinase inhibitors
Imatinib Mesylate
risk
hepatitis b virus
imatinib
nilotinib
nilotinib
bosutinib
bosutinib
Dasatinib
dasatinib
ponatinib hydrochloride
ponatinib
Tyrosine Kinase Inhibitor
Hepatitis B reactivation
guidelines for drug use
continuity of patient care
mass screening
hepatitis B
hepatitis B
Tyrosine Kinase Inhibitors
nilotinib
ponatinib
pyrimidines
imidazoles
pyridazines
aniline compounds
nitriles
quinolines
---
http://www.e-cancer.fr/content/download/126025/1524695/file/Médicaments%20ciblant%20BCR-ABL.pdf
2015
false
false
false
France
French
practice guideline
guidelines for drug use
administration, oral
antineoplastic agents
Drug-Related side effects and adverse reactions
imatinib
dasatinib
nilotinib
nilotinib
bosutinib
bosutinib
ponatinib
ponatinib
protein kinase inhibitors
ruxolitinib
ruxolitinib
janus kinases
information dissemination
continuity of patient care
hospital-physician relations
hospital-patient relations
physician-patient relations
drug interactions
pregnancy
protein-tyrosine kinases
Tyrosine Kinase Inhibitor
Dasatinib
Imatinib Mesylate
Tyrosine Kinase Inhibitors
nilotinib
ruxolitinib
pyrazoles
aniline compounds
nitriles
quinolines
imidazoles
pyridazines
---
http://www.meddispar.fr/Medicaments/INTELENCE-25-B-120/(type)/letter/(value)/I/(cip)/3400926887629
2014
false
false
false
drug information
etravirine
etravirine
administration, oral
drug prescriptions
legislation, drug
anti-hiv agents
pyridazines
---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=66595716
2014
false
false
false
France
French
summary of product characteristics
package leaflet
tablets
etravirine
pill, nos
etravirine
compression, nos
pyridazines
---
https://www.ema.europa.eu/medicines/human/EPAR/Volibris
2012
false
United Kingdom
English
French
Endothelin A Receptor Antagonists
Endothelin A Receptor Antagonists
syndication feed
ambrisentan
ambrisentan
phenylpropionates
pyridazines
pyridazines
drug approval
drug labeling
treatment outcome
drug evaluation
orphan drug production
tablets
administration, oral
hypertension, pulmonary
adult
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
phenylpropionates
ambrisentan
drug evaluation
summary of product characteristics
package leaflet
---